Please login to the form below

Not currently logged in
Email:
Password:

Sinclair and IS plan to merge

Sinclair Pharma has announced plans for a potential merger with IS Pharma to create a new Europe-wide speciality pharma company

Sinclair Pharma and IS Pharma are in 'advanced discussions' regarding the creation of a new Europe-wide speciality pharma company, according to a statement from Sinclair.

Sinclair IS Pharma, as the new company is planned to be named, would be headquartered in the UK, with a focus on developing products in dermatology and specialist hospital therapies.

Existing therapies from the portfolios of both Sinclair and IS would continue to be developed and marketed, with the new combined company also having in-house development capability.

As it stands, a deal would be an all-share offer from Sinclair, with IS shareholders receiving 2.69 Sinclair shares per one IS share.

Shareholders of Sinclair would own 62.4 per cent of the new company while IS shareholders would have 37.6 per cent.

As well as covering Europe, Sinclair said following the proposed merger, the new company 'would continue to access the substantial growth opportunities in emerging markets through existing and new regional strategic partnerships'.

Any deal depends on a unanimous recommendation by the board of IS regarding any offer from Sinclair.

14th February 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...
Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...

Infographics